All sponsors

Cabaletta Bio $CABA

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-20
ACTIVE TRIALS5
PHASE 3 / 2-32
RECRUITING5
READOUTS ≤12 MONTHS0
READOUT SLIPPED >6 MO60%

Delay Index: of 5 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +14.0 months). See all sponsors →

Open Cabaletta Bio on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
CABA-201 following preconditioning with fludarabine and cyclophosphamide
NCT06154252
P2/3RecruitingIdiopathic Inflammatory Myopathy; Dermatomyositis742028-07
DSG3-CAART
NCT04422912
P1/2RecruitingPemphigus Vulgaris402029-01 (+29 mo)
CABA-201
NCT06328777
P2/3RecruitingSystemic Sclerosis; Scleroderma372029-07
CABA-201
NCT06359041
P1/2RecruitingGeneralized Myasthenia Gravis (gMG)242029-09 (+14 mo)
CABA-201
NCT06121297
P1/2RecruitingSystemic Lupus Erythematosus; Lupus Nephritis282029-12 (+24 mo)